Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis
factor-α (TNFα), a proinflammatory cytokine with an increased expression in the inflamed …

IBD includes two classic entities, Crohn's disease and ulcerative colitis, and a third
undetermined form (IBD-U), characterized by a chronic relapsing course resulting in a high …

В статье представлен финальный вариант проект протокола по диагностике и лечению
болезни Крона у детей, разработанный экспертами Российского общества детских …

Introduction: Anti-tumor necrosis factor-alpha (TNF-α) therapy has revolutionized the
medical treatment of Crohn's disease (CD). Nevertheless, anti-TNF-α therapy has been …

Objectives To develop and/or update fact sheets about TNFα antagonists treatments, in
order to assist physicians in the management of patients with inflammatory joint disease …

Background Psoriasis has an estimated prevalence of 0.5% to 2.0% in children. There is a
paucity of data regarding the management and safety of treatments currently available for …

Introduction: Adalimumab is used to treat children with Crohn's disease (CD), but the effects
of adalimumab on growth in CD have not been studied. Aim: To study growth and disease …

Background and aims Biological agents are being increasingly used in the UK for paediatric-
onset inflammatory bowel disease (PIBD) despite limited evidence and safety concerns. We …

Objectives: European Crohn's Colitis Organization (ECCO) and the European Society of
Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines recommend …

Pediatric Crohn's disease commonly presents with moderate-to-severe intestinal
inflammation with a greater risk of complications if remission is not achieved. Anti-tumor …